Sodium-Glucose Co-Transporter 2 Inhibitors: Mechanism of Action and Efficacy in Non-Diabetic Kidney Disease from Bench to Bed-Side

Aly M. Abdelrahman; Alaa S. Awad; Emaad M. Abdel-Rahman

doi:10.3390/jcm13040956

Sodium-Glucose Co-Transporter 2 Inhibitors: Mechanism of Action and Efficacy in Non-Diabetic Kidney Disease from Bench to Bed-Side

Aly M. Abdelrahman, Alaa S. Awad, Emaad M. Abdel-Rahman^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are currently available for the management of type 2 diabetes mellitus. SGLT2i acts by inhibiting renal SGLT2, thereby increasing glucosuria and lowering serum glucose. Recent trials are emerging supporting a role for SGLT2i irrespective of the diabetic status pointing towards that SGLT2i have other mechanisms of actions beyond blood sugar control. In this review, we will shed light on the role of this group of medications that act as SGLT2i in non-diabetics focusing on pre-clinical and clinical data highlighting the mechanism of renoprotection and effects of SGLT2i in the non-diabetic kidneys.

Original language	English
Article number	956
Journal	Journal of Clinical Medicine
Volume	13
Issue number	4
DOIs	https://doi.org/10.3390/jcm13040956
Publication status	Published - Feb 7 2024
Externally published	Yes

Keywords

blood pressure
CKD
FSGS
IgAN
non-diabetics
proteinuria
SGLT2i
survival

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/jcm13040956

Cite this

@article{b76f8e785a4a4626a84d4a88c3a82005,

title = "Sodium-Glucose Co-Transporter 2 Inhibitors: Mechanism of Action and Efficacy in Non-Diabetic Kidney Disease from Bench to Bed-Side",

abstract = "Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are currently available for the management of type 2 diabetes mellitus. SGLT2i acts by inhibiting renal SGLT2, thereby increasing glucosuria and lowering serum glucose. Recent trials are emerging supporting a role for SGLT2i irrespective of the diabetic status pointing towards that SGLT2i have other mechanisms of actions beyond blood sugar control. In this review, we will shed light on the role of this group of medications that act as SGLT2i in non-diabetics focusing on pre-clinical and clinical data highlighting the mechanism of renoprotection and effects of SGLT2i in the non-diabetic kidneys.",

keywords = "blood pressure, CKD, FSGS, IgAN, non-diabetics, proteinuria, SGLT2i, survival",

author = "Abdelrahman, {Aly M.} and Awad, {Alaa S.} and Abdel-Rahman, {Emaad M.}",

note = "Publisher Copyright: {\textcopyright} 2024 by the authors.",

year = "2024",

month = feb,

day = "7",

doi = "10.3390/jcm13040956",

language = "English",

volume = "13",

journal = "Journal of Clinical Medicine",

issn = "2077-0383",

publisher = "MDPI AG",

number = "4",

}

TY - JOUR

T1 - Sodium-Glucose Co-Transporter 2 Inhibitors

T2 - Mechanism of Action and Efficacy in Non-Diabetic Kidney Disease from Bench to Bed-Side

AU - Abdelrahman, Aly M.

AU - Awad, Alaa S.

AU - Abdel-Rahman, Emaad M.

PY - 2024/2/7

Y1 - 2024/2/7

N2 - Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are currently available for the management of type 2 diabetes mellitus. SGLT2i acts by inhibiting renal SGLT2, thereby increasing glucosuria and lowering serum glucose. Recent trials are emerging supporting a role for SGLT2i irrespective of the diabetic status pointing towards that SGLT2i have other mechanisms of actions beyond blood sugar control. In this review, we will shed light on the role of this group of medications that act as SGLT2i in non-diabetics focusing on pre-clinical and clinical data highlighting the mechanism of renoprotection and effects of SGLT2i in the non-diabetic kidneys.

AB - Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are currently available for the management of type 2 diabetes mellitus. SGLT2i acts by inhibiting renal SGLT2, thereby increasing glucosuria and lowering serum glucose. Recent trials are emerging supporting a role for SGLT2i irrespective of the diabetic status pointing towards that SGLT2i have other mechanisms of actions beyond blood sugar control. In this review, we will shed light on the role of this group of medications that act as SGLT2i in non-diabetics focusing on pre-clinical and clinical data highlighting the mechanism of renoprotection and effects of SGLT2i in the non-diabetic kidneys.

KW - blood pressure

KW - CKD

KW - FSGS

KW - IgAN

KW - non-diabetics

KW - proteinuria

KW - SGLT2i

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85187282034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85187282034&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/4caf7114-149f-301e-be80-9569527eb102/

U2 - 10.3390/jcm13040956

DO - 10.3390/jcm13040956

M3 - Article

C2 - 38398269

AN - SCOPUS:85187282034

SN - 2077-0383

VL - 13

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

IS - 4

M1 - 956

ER -

Sodium-Glucose Co-Transporter 2 Inhibitors: Mechanism of Action and Efficacy in Non-Diabetic Kidney Disease from Bench to Bed-Side

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this